Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

NY-ESO-1 Peptide Vaccine

Vaccine (Peptide vaccine) · Immune activation, directed at NY-ESO-1 (CTAG1B)

Phase 2 Most advanced trial

1 Registered trials

What is NY-ESO-1 Peptide Vaccine?

NY-ESO-1 Peptide Vaccine is a cancer vaccine made of an immunogenic peptide derived from the cancer-testis antigen NY-ESO-1, which is found in normal testis and various tumors. It is intended to stimulate humoral and cytotoxic T lymphocyte responses against NY-ESO-1-expressing cells. It is studied in ovarian cancer.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type: Vaccine (Peptide vaccine)
Targets: NY-ESO-1 (CTAG1B) (antigen)
Mechanism: Immune activation, directed at NY-ESO-1 (CTAG1B)
Therapy area: Oncology
In trials of: CHRS
FDA status: Investigational, not approved in the US. Most advanced trial: Phase 2

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT05479045	Phase 2	Ovarian Cancer Stage IV	Not yet recruiting	CHRS

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Ovarian Cancer Stage 3Ovarian Cancer Stage IIIOvarian Cancer Stage IV

Sources

Updated Oct 11, 2026.

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z